ClinicalTrials.gov

History of Changes for Study: NCT03442985
An Efficacy and Safety Study of Palovarotene for the Treatment of MO (MO-Ped)
Latest version (submitted December 10, 2019) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 21, 2018 None (earliest Version on record)
2 March 5, 2018 Study Status
3 March 21, 2018 Study Status and Contacts/Locations
4 March 22, 2018 Recruitment Status, Study Status and Oversight
5 April 25, 2018 Study Status and Study Description
6 June 21, 2018 Study Status and Contacts/Locations
7 June 26, 2018 Contacts/Locations and Study Status
8 July 12, 2018 Contacts/Locations and Study Status
9 September 20, 2018 Study Status and Contacts/Locations
10 October 9, 2018 Contacts/Locations and Study Status
11 October 17, 2018 Outcome Measures, Study Status and Eligibility
12 October 30, 2018 Contacts/Locations and Study Status
13 November 13, 2018 Contacts/Locations and Study Status
14 December 19, 2018 Study Status and Contacts/Locations
15 January 10, 2019 Study Status and Contacts/Locations
16 January 17, 2019 Contacts/Locations and Study Status
17 February 5, 2019 Study Status and Contacts/Locations
18 February 12, 2019 Contacts/Locations and Study Status
19 February 22, 2019 Contacts/Locations and Study Status
20 February 25, 2019 Contacts/Locations and Study Status
21 March 4, 2019 Contacts/Locations and Study Status
22 March 5, 2019 Contacts/Locations and Study Status
23 March 21, 2019 Contacts/Locations and Study Status
24 April 16, 2019 Study Status and Contacts/Locations
25 June 6, 2019 Contacts/Locations and Study Status
26 June 20, 2019 Contacts/Locations and Study Status
27 July 2, 2019 Study Status and Contacts/Locations
28 August 16, 2019 Contacts/Locations and Study Status
29 September 10, 2019 Contacts/Locations and Study Status
30 September 17, 2019 Contacts/Locations and Study Status
31 September 18, 2019 Contacts/Locations and Study Status
32 September 20, 2019 Contacts/Locations and Study Status
33 December 10, 2019 Recruitment Status, Contacts/Locations and Study Status
Comparison Format:

Scroll up to access the controls

Changes (Side-by-Side) for Study: NCT03442985
February 21, 2018 (v1) -- August 16, 2019 (v28)

Changes in: Study Status, Outcome Measures, Contacts/Locations, Eligibility, Study Description and Oversight

Study Identification
Unique Protocol ID: PVO-2A-201 PVO-2A-201
Brief Title: An Efficacy and Safety Study of Palovarotene for the Treatment of MO (MO-Ped)An Efficacy and Safety Study of Palovarotene for the Treatment of MO (MO-Ped)
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
Secondary IDs:
Study Status
Record Verification: February 2018 August 2019
Overall Status: Not yet recruiting Recruiting
Study Start: February 2018 April 20, 2018
Primary Completion: January 2021 [Anticipated ] January 2021 [Anticipated ]
Study Completion: February 2021 [Anticipated ] February 2021 [Anticipated ]
First Submitted: October 11, 2017 October 11, 2017
First Submitted that
Met QC Criteria:
February 21, 2018 February 21, 2018
First Posted: February 22, 2018 [Actual ] February 22, 2018 [Actual ]
Last Update Submitted that
Met QC Criteria:
February 21, 2018 August 16, 2019
Last Update Posted: February 22, 2018 [Actual ] August 20, 2019 [Actual ]
Sponsor/Collaborators
Sponsor: Clementia Pharmaceuticals Inc. Clementia Pharmaceuticals Inc.
Responsible Party: Sponsor Sponsor
Collaborators:
Oversight
U.S. FDA-regulated Drug: Yes Yes
U.S. FDA-regulated Device: No No
Data Monitoring: Yes Yes
Study Description
Brief Summary: This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO). This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO).
Detailed Description: Multiple osteochondromas is a rare condition where children develop multiple benign cartilage-capped bony tumors called osteochondromas on bones throughout the body, resulting in pain, deformity, limb length discrepancy, disability, and eventually arthritis and possible malignancy. The primary objective is to compare the efficacy of two dosage regimens of palovarotene with placebo to prevent the formation of new osteochondromas in pediatric MO subjects with exostosin 1 or exostosin 2 gene mutations. Osteochondroma formation will be assessed by whole body magnetic resonance imaging (MRI). Secondary efficacy objectives are to compare the effect of palovarotene on the volume of osteochondromas as assessed by MRI; and on the annualized rate of new or worsening deformities and MO-related surgeries. The overall safety of palovarotene and the effects of palovarotene on linear growth, bone growth plates, bone mineral density, quality of life, and pain due to osteochondromas will also be studied.
Conditions
Conditions: Exostoses, Multiple Hereditary Exostoses, Multiple Hereditary
Keywords: Multiple osteochondromas
Osteochondroma
Palovarotene
Hereditary multiple exostoses
HME
MO
Retinoic acid receptor gamma agonist
Retinoic acid receptor agonist
Multiple osteochondromas
Osteochondroma
Palovarotene
Hereditary multiple exostoses
HME
MO
Retinoic acid receptor gamma agonist
Retinoic acid receptor agonist
Study Design
Study Type: InterventionalInterventional
Primary Purpose: TreatmentTreatment
Study Phase: Phase 2Phase 2
Interventional Study Model: Parallel Assignment Parallel Assignment
Number of Arms: 33
Masking: QuadrupleParticipant, Care Provider, Investigator, Outcomes AssessorQuadrupleParticipant, Care Provider, Investigator, Outcomes Assessor
Allocation: RandomizedRandomized
Enrollment: 240 [Anticipated ] 240 [Anticipated ]
Arms and Interventions
Arms Assigned Interventions
Experimental: Palovarotene 2.5 mg daily regimen Drug: Palovarotene 2.5 mg
Subjects will receive a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
Experimental: Palovarotene 5.0 mg daily regimen Drug: Palovarotene 5.0 mg
Subjects will receive a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
Placebo Comparator: Placebo regimen Placebo
Subjects will receive placebo, once daily, for up to 24 months.
Outcome Measures
Primary Outcome Measures:
1. Annualized rate of new osteochondromas
The annualized rate of new osteochondromas as assessed by whole body magnetic resonance imaging (MRI).

[Time Frame: Month 24 ]
Annualized rate of new osteochondromas
The annualized rate of new osteochondromas as assessed by whole body magnetic resonance imaging (MRI).

[Time Frame: Month 24 ]
Secondary Outcome Measures:
2. Total volume of osteochondromas
The change from baseline in the total volume of osteochondromas as assessed by whole body MRI.

[Time Frame: Months 12 and 24/end-of-treatment (EOT) ]
Total volume of osteochondromas
The change from baseline in the total volume of osteochondromas as assessed by whole body MRI.

[Time Frame: Months 12 and 24/end-of-treatment (EOT) ]
3. Annualized rate of new or worsening deformities
The annualized rate of new or worsening deformities as assessed by radiographic imaging of both upper and lower limbs.

[Time Frame: Months 12 and 24/EOT ]
Annualized rate of new or worsening deformities
The annualized rate of new or worsening deformities as assessed by radiographic imaging of both upper and lower limbs.

[Time Frame: Months 12 and 24/EOT ]
4. Annualized rate of MO-related surgeries
The annualized rate of MO-related surgeries. Surgeries include surgical excisions of a symptomatic osteochondroma and surgical procedures to correct a joint deformities or functional limitations.

[Time Frame: Months 12 and 24/EOT ]
Annualized rate of MO-related surgeries
The annualized rate of MO-related surgeries. Surgeries include surgical excisions of a symptomatic osteochondroma and surgical procedures to correct a joint deformities or functional limitations.

[Time Frame: Months 12 and 24/EOT ]
5. Palovarotene area under the concentration-time curve (AUC)
Determination of AUC at steady-state assessed during treatment.

[Time Frame: Month 1 ]
Palovarotene area under the concentration-time curve (AUC)
Determination of AUC at steady-state assessed during treatment.

[Time Frame: Month 1 ]
6. Palatability
The palatability of the drug product versus placebo when sprinkled onto specific foods as assessed by a five-point hedonic face scale.

[Time Frame: Day 1 and Month 1 ]
Other Pre-specified Outcome Measures:
7. Safety of Palovarotene: Monitoring of adverse events
Monitoring of adverse events.

[Time Frame: Study Day 1; and from Months 1 to 36/ET at every subject contact ]
Safety of Palovarotene: Monitoring of adverse events
Monitoring of adverse events.

[Time Frame: Study Day 1; and from Months 1 to 30/ET at every subject contact ]
8. Volume of osteochondroma cartilage cap
Change from baseline in the total volume of cartilage cap of osteochondromas as assessed by whole body MRI

[Time Frame: Months 12 and 24 ]
9. Annualized rate of new or worsening functional limitations
The annualized rate of new or worsening functional limitations. Functional limitations are defined as restrictions in joint range of motion.

[Time Frame: Months 12 and 24/EOT ]
Annualized rate of new or worsening functional limitations
The annualized rate of new or worsening functional limitations. Functional limitations are defined as restrictions in joint range of motion.

[Time Frame: Months 12 and 24/EOT ]
10. PedsQL
The Pediatric Quality of Life Inventory (PedsQL, version 4.0) questionnaire to assess quality of life.

[Time Frame: Months 6, 12, 18, and 24/EOT ]
PedsQL
The Pediatric Quality of Life Inventory (PedsQL, version 4.0) questionnaire to assess quality of life.

[Time Frame: Months 6, 12, 18, and 24/EOT ]
11. PROMIS Global Health Scale
The Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference pediatric item bank to assess the effect of pain on daily activities.

[Time Frame: Months 6, 12, 18, and 24/EOT ]
PROMIS Global Health Scale
The Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference pediatric item bank to assess the effect of pain on daily activities.

[Time Frame: Months 6, 12, 18, and 24/EOT ]
12. FPS-R
The Faces Pain Scale - Revised (FPS-R) to assess pain intensity.

[Time Frame: Months 6, 12, 18, and 24/EOT ]
FPS-R
The Faces Pain Scale - Revised (FPS-R) to assess pain intensity.

[Time Frame: Months 6, 12, 18, and 24/EOT ]
Eligibility
Minimum Age: 2 Years 2 Years
Maximum Age: 14 Years 14 Years
Sex: All All
Gender Based:
Accepts Healthy Volunteers: NoNo
Criteria:

Key Inclusion Criteria:

  • Written, signed, and dated informed subject/parent consent and age-appropriate assent (performed according to local regulations).
  • A clinical diagnosis of MO with exostosin 1 or 2 gene mutations.
  • Male or female from 2 to 14 years of age.
  • Female subjects must be premenarchal at screening.
  • A bone age at screening of 14 years or less.
  • Symptomatic MO, defined as a new or enlarged osteochondroma that occurred in the preceding 12 months, a painful osteochondroma, a skeletal deformity, a joint limitation, or prior surgery for a MO-related complication.
  • The ability to undergo whole body MRI without general anesthesia requiring intubation.
  • Abstinent or using two highly effective forms of birth control.

Key Exclusion Criteria:

  • Weight under 10 kg.
  • Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.
  • Any subject with neurologic signs suggestive of spinal cord impingement.
  • Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4 activity.
  • Amylase or lipase >2 times the above the upper limit of normal (>2×ULN) or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.
  • Any surgical implant that is contraindicated for MRI.

Key Inclusion Criteria:

  • Written, signed, and dated informed subject/parent consent and age-appropriate assent (performed according to local regulations).
  • A clinical diagnosis of MO with disease-causing exostosin 1 or 2 gene mutations.
  • Male or female from 2 to 14 years of age.
  • Female subjects must be premenarchal at screening.
  • A bone age at screening of 14 years or less.
  • Symptomatic MO, defined as five or more clinically-evident osteochondromas and a new or enlarged osteochondroma that occurred in the preceding 12 months, five or more clinically-evident osteochondromas and the presence of a painful osteochondroma, a skeletal deformity, a joint limitation, or prior surgery for a MO-related complication.
  • The ability to undergo whole body MRI with or without sedation/general anesthesia.
  • Use of two effective methods of birth control during treatment, and for 1 month after treatment discontinuation, unless committed to true abstinence from heterosexual sex. Sexually active females of child-bearing potential must also agree to start effective methods of birth control at screening.

Key Exclusion Criteria:

  • Weight under 10 kg.
  • Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.
  • Any subject with neurologic signs suggestive of spinal cord impingement.
  • Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4 activity.
  • Amylase or lipase >2 times the above the upper limit of normal (>2×ULN) or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.
  • Any surgical implant that is contraindicated for MRI.
Contacts/Locations
Central Contact: Clementia Call Center (US/Canada Only)
Telephone: 1-800-750-8710
Email: ClinicalTrials@clementiapharma.com
Clementia Call Center (US/Canada Only)
Telephone: 1-800-750-8710
Email: ClinicalTrials@clementiapharma.com
Locations: United States, California
Children's Orthopaedic Center
[Recruiting]
Los Angeles, California, United States, 90027
Contact: Regina Woon 323-361-2843 rwoon@chla.usc.edu
Principal Investigator: Vernon T Tolo, MD
Sub-Investigator: Rachel Y Goldstein, MD, MPH
Shriners Hospital for Children - Sacramento
[Recruiting]
Sacramento, California, United States, 95817
Contact: Elizabeth Molnar 916-453-2136 emolnar@shrinenet.org
Principal Investigator: Michelle James, MD
Sub-Investigator: Holly Leshikar, MD
University of California-San Francisco
[Recruiting]
San Francisco, California, United States, 94158
Contact: Emma Canepa 415-502-2425 Emma.Canepa@ucsf.edu
Principal Investigator: Jessica Tenney, MD
Sub-Investigator: Edward Hsiao, MD
Sub-Investigator: Janet Lee, MD
United States, District of Columbia
Children's National Medical Center
[Recruiting]
Washington, District of Columbia, United States, 20010
Contact: Melissa Lynn Salerno 202-476-2142 msalerno@childrensnational.org
Contact: Suzie Goodick 202 476 2142 mgoodick@childrensnational.org
Principal Investigator: AeRang Kim, MD
Sub-Investigator: Robert Henshaw, MD
United States, Florida
Paley Orthopedic and Spine Institute
[Recruiting]
West Palm Beach, Florida, United States, 330407
Contact: Troy Rand 561-531-1553 trand@paleyinstitute.org
Principal Investigator: David Feldman, MD
Sub-Investigator: Drod Paley, MD
Sub-Investigator: Craig Robbins, MD
United States, Illinois
Shriners Hospital for Children - Chicago
[Recruiting]
Chicago, Illinois, United States, 60707
Contact: Kerry O'Rourke, MS 773-385-5532 korourke@shrinenet.org
Principal Investigator: Jeffrey Ackman, MD
Sub-Investigator: Haluk Altiok, MD
Sub-Investigator: Purnendu Gupta, MD
Sub-Investigator: Peter Smith, MD
United States, Maryland
Johns Hopkins University
[Recruiting]
Baltimore, Maryland, United States, 21205
Contact: Elizabeth Walek 410-502-7525 ewalek1@jhmi.edu
Principal Investigator: Nara Sobreira, MD, PhD
Sub-Investigator: Julie Hoover-Fong, MD, PhD
United States, Massachusetts
Boston Children's Hospital
[Recruiting]
Boston, Massachusetts, United States, 02115
Contact: Andrea Hale 617-919-2867 Andrea.Hale@childrens.harvard.edu
Principal Investigator: Christina Jacobsen, MD
Sub-Investigator: Ingrid Holm, MD, MPH
Sub-Investigator: Samantha Spencer, MD
United States, Minnesota
Mayo Clinic - PPDS
[Recruiting]
Rochester, Minnesota, United States, 55905
Contact: Karen Cavanaugh, CCRP 507-266-7837 Cavanaugh.karen@mayo.edu
Principal Investigator: Robert Pignolo, MD
Sub-Investigator: Noelle Larson, MD
Sub-Investigator: Matthew Drake, MD
Sub-Investigator: Stephen Broski, MD
Sub-Investigator: Alexander Meves, MD
United States, Oregon
Shriners Hospitals for Children - Portland
[Recruiting]
Portland, Oregon, United States, 97239
Contact: Cathleen Buckon, MS 503-221-3471 cbuckon@shrinenet.org
Principal Investigator: Krister Freese, MD
Sub-Investigator: Daniel J. Bouton, MD
Sub-Investigator: Cathleen E. Buckon, MS
Sub-Investigator: Susan Sienko, PhD
Sub-Investigator: Ann Reina, PharmD
Sub-Investigator: Amy Mori, PharmD
Sub-Investigator: Pam Scott, RN
Sub-Investigator: Brooke Nelson, RN
United States, Pennsylvania
The Children's Hospital of Philadelphia (CHOP)
[Recruiting]
Philadelphia, Pennsylvania, United States, 19104
Contact: Vashisht Arshanapally, BS 267-426-7482 arshanapav@email.chop.edu
Principal Investigator: Michael A Levine, MD
Sub-Investigator: Edna Mancilla, MD
Shriners Hospital for Children - Philadelphia
[Recruiting]
Philadelphia, Pennsylvania, United States, 19410-4160
Contact: Gregory Wright 215-430-4248 gwright@shrinenet.org
Principal Investigator: Bethany Lipa, MD
Sub-Investigator: Scott Kozin, MD
Sub-Investigator: Dan Zlotolow, MD
Sub-Investigator: Richard Goldberg, MD
United States, Texas
Memorial Hermann Hospital
[Recruiting]
Houston, Texas, United States, 77030
Contact: Mayank Rao 713-704-2639 Mayank.Rao@uth.tmc.edu
Principal Investigator: Ernest Conrad, MD
Sub-Investigator: Shiraz Younas, MD
Australia, New South Wales
Westmead Children's Hospital
[Recruiting]
Westmead, New South Wales, Australia, 2145
Contact: Emily Fuller +61 2 9845 0429 emily.fuller@health.nsw.gov.au
Principal Investigator: Andreas Zankl, MD
Sub-Investigator: Craig Munns, MD
Belgium, Antwerp
UZ Antwerpen
[Recruiting]
Edegem, Antwerp, Belgium
Contact: Iris Verhaegen +32 3 821 35 44 iris.verhaegen@uza.be
Principal Investigator: Geert Mortier, MD
Canada, Ontario
Hospital for Sick Children
[Recruiting]
Toronto, Ontario, Canada, M5G 1X8
Contact: Tony (Yongyao) Tan (416) 813-7654 Ext. 203575 tony.tan@sickkids.ca
Principal Investigator: Roberto Mendoza-Londono, MD
Sub-Investigator: Lucie Dupuis, MD
Sub-Investigator: Andrew Howard, MD
Sub-Investigator: Jennifer Stimec, MD
Sub-Investigator: Irene Lara-Corrales, MD
Sub-Investigator: Peter Kannu, MD
Canada, Quebec
Centre Hospitalier Universitaire Sainte-Justine
[Recruiting]
Montréal, Quebec, Canada, H3T 1C5
Contact: Christine Massicotte (514) 345-4931 Ext. 3209 christine.massicotte@recherche-ste-justine.qc.ca
Principal Investigator: Philippe Campeau, MD
Sub-Investigator: Mathilde Debeurme, MD
Shriners Hospital for Children - Canada
[Recruiting]
Montréal, Quebec, Canada, H4A 0A9
Contact: Kathleen Montpetit (514) 842-4464 Ext. 2263 kmontpetit@shrinenet.org
Principal Investigator: Reggie Hamdy, MD
Sub-Investigator: Chantal Janelle, MD
France
Hôpital universitaire Necker - Enfants Malades
[Recruiting]
Paris, France, 75015
Contact: Kim-Hanh Le Quan Sang +33144495951 kh.lequansang@aphp.fr
Principal Investigator: Valerie Cormier-Daire, MD
Sub-Investigator: Genevieve Baujat, MD
Hôpital des Enfants, CHU de Toulouse
[Recruiting]
Toulouse, France, 31059
Contact: Françoise Auriol +33567771095 auriol.f@chu-toulouse.fr
Principal Investigator: Pr Jean Pierre Salles
Sub-Investigator: Valerie Porquet-Bordes, MD
Sub-Investigator: Thomas Edouard, MD
Sub-Investigator: Franck Accadbled, MD
Italy, Emilia-Romagna
Istituti Ortopedici Rizzoli
[Recruiting]
Bologna, Emilia-Romagna, Italy, 40136
Contact: Giuliana Nervutti +30 0516366681 giuliana.nervuti@ior.it
Principal Investigator: Luca Sangiorgi, MD, PhD
Japan, Aiti
Nagoya University Hospital
[Recruiting]
Nagoya, Aiti, Japan
Contact: Kumiko Tsukamoto +81-52-561-0166 kumiko-tsukamoto@irom.co.jp
Principal Investigator: Masaki Matsushita, MD
Japan, Osaka
Osaka University Hospital
[Recruiting]
Suita, Osaka, Japan, 565-0871
Contact: Hiromi Tanaka (SC) +81662108290 h-tanaka@dmi.med.osaka-u.ac.jp
Principal Investigator: Keiichi Ozono, MD, PhD
Sub-Investigator: Taichi Kitaoka, MD
Sub-Investigator: Hiroyuki Saitou, MD
Sub-Investigator: Dr. Kiyoshi Yoshida
Sub-Investigator: Dr. Hidetatsu Otani
Sub-Investigator: Dr. Kenichiro Hamada
Sub-Investigator: Dr. Satoshi Takenaka
Sub-Investigator: Hiroto Takahashi, MD
Netherlands, Noord-Holland
OLVG locatie Oost
[Recruiting]
Amsterdam, Noord-Holland, Netherlands, 1091 AC
Contact: Arnard van der Zwan +31205993653 moped@olvg.nl
Principal Investigator: Arnard van der Zwan, MD
Portugal
Hospital Pediátrico de Coimbra
[Recruiting]
Coimbra, Portugal, 3000-602
Contact: Carla Neta +351 239 400 477 carlaneta@chuc.min-saude.pt
Principal Investigator: Luisa Diogo Matos, MD
Sub-Investigator: Sergio Sousa, MD
Sub-Investigator: Inês Balacó
Sub-Investigator: Sofia Fernandes
Sub-Investigator: Paula Garcia
Sub-Investigator: Cristina Alves
Spain
Hospital Universitario La Paz
[Recruiting]
Madrid, Spain, 28046
Contact: Vega Mauleon Martinez +34912071876 vegamauleon@gmail.com
Principal Investigator: Fernando Santos Simarro, MD
Sub-Investigator: Gaspar González Morán, MD
Sub-Investigator: Karen Heath, MD
Turkey, Izmir
Ege University Medical Faculty Hospital
[Recruiting]
Bornova, Izmir, Turkey
Contact: Assoc. Prof. Dr. Levent Kucuk +905055250277 kucuklevent@yahoo.com
Principal Investigator: Assoc. Prof. Dr. Levent Kucuk
Sub-Investigator: Özgür Mert Bakan
Sub-Investigator: Dilek Bayraktar
Sub-Investigator: Andac Celasun Alsina
Sub-Investigator: Hüseyin Günay
Sub-Investigator: Esra Işık
Sub-Investigator: Tahir Atik
Turkey
Bezmialem Vakif University Medical Faculty Hospital
[Recruiting]
Istanbul, Turkey, 34093
Contact: Assoc. Prof. Gozde Yesil +90506 648 7808 gozdeyesil@msn.com
Principal Investigator: Assoc. Prof. Gozde Yesil
Sub-Investigator: Ayca Dilruba Aslanger, MD
Sub-Investigator: Gokcer Uzer, MD
United Kingdom
Evelina London Children's Hospital
[Recruiting]
London, United Kingdom, SE1 7EH
Contact: Shelley Mieres +44(0)20 7188 7188 shelley.mieres@gstt.nhs.uk
Principal Investigator: Melita Irving, MD
Royal Manchester Childrens Hospital
[Recruiting]
Manchester, United Kingdom, M13 9WL
Contact: Michelle Hepburn +441617011628 Michelle.Hepburn@mft.nhs.uk
Principal Investigator: Mars Skae, MBChB
Sub-Investigator: Raja Padidela, MBBS
Royal National Orthopaedic Hospital
[Recruiting]
Stanmore, United Kingdom, HA7 4LP
Contact: Andy Symonds +442089095825 a.symonds@nhs.net
Principal Investigator: Zilla Huma, MD
IPDSharing
Plan to Share IPD: No No
References
Citations: Inubushi T, Lemire I, Irie F, Yamaguchi Y. Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses. J Bone Miner Res. 2018 Apr;33(4):658-666. doi: 10.1002/jbmr.3341. Epub 2017 Nov 30. PubMed 29120519Inubushi T, Lemire I, Irie F, Yamaguchi Y. Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses. J Bone Miner Res. 2018 Apr;33(4):658-666. doi: 10.1002/jbmr.3341. Epub 2017 Nov 30. PubMed 29120519
Links: URL: http://www.mhecoalition.org/ Exit Disclaimer; please review our Privacy Policy
Description: MHE Coalition
URL: http://www.mhecoalition.org/ Exit Disclaimer; please review our Privacy Policy
Description: MHE Coalition
URL: http://www.mherf.org/ Exit Disclaimer; please review our Privacy Policy
Description: MHE Research Foundation
URL: http://www.mherf.org/ Exit Disclaimer; please review our Privacy Policy
Description: MHE Research Foundation
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services